Weight-Loss Drugs Help Push Dallas Health Plan $17 Million Over Budget

Dallas began its current fiscal year expecting to save about $12 million on employee healthcare. Instead, the city's employee benefits fund is now projected to finish roughly $17 million over budget — a nearly $29 million swing from what officials originally anticipated.

According to Dallas budget documents, employee benefit expenses are forecast to exceed budget by about $17.1 million because of higher overall health plan costs. Increased use of GLP-1 medications and several exceptionally expensive medical claims were identified as contributing factors.

The headline may look like it's about weight-loss drugs. The larger story is a question that employers, insurers, and public health plans across America are struggling to answer: what happens when a medication can meaningfully improve someone's health, but widespread coverage threatens the financial stability of the plan paying for it?

Dallas expected savings and got a cost surprise

Employee health plans run on estimates of how much medical care and prescription use will cost in the coming year. Employers use those projections to set budgets, determine employee contributions, and decide what the plan can afford to cover. But healthcare costs are hard to predict — a small number of major medical events can generate millions in unexpected claims, and a new medication can create pressure when utilization grows faster than projected.

Dallas hit both problems. The city's April 2026 budget accountability report projected employee benefits expenses about $17.1 million over budget, attributing the overage to higher health plan costs including increased GLP-1 utilization and high-cost claimants.

What are GLP-1 medications?

GLP-1 medications were first developed to help people with Type 2 diabetes regulate blood sugar. Some are also approved for chronic weight management. Common brand names include Ozempic, Wegovy, Mounjaro, and Zepbound, though the drugs don't all carry identical approvals or uses.

These medications can help eligible patients achieve substantial weight loss, improve certain obesity-related conditions, and reduce health risks for some patients when prescribed and monitored appropriately. That clinical potential explains why demand has grown so quickly. Obesity isn't simply a cosmetic concern — it's associated with diabetes, cardiovascular disease, sleep apnea, joint problems, and other conditions that can create significant long-term expense. Treating obesity earlier could potentially prevent more serious and costly conditions later.

From an employer's financial perspective, though, those future savings may take years to appear while the prescription expense begins immediately. That timing difference creates the conflict.

The employer pays today for savings that may come later

An employer plan may spend thousands of dollars a year for each employee or dependent using a GLP-1. The employer hopes the treatment eventually reduces hospitalizations, diabetes complications, cardiovascular events, or other expensive needs. But those savings aren't guaranteed to come quickly. The employee may leave before the long-term benefit is realized; the patient may stop treatment; the drug may improve health without generating enough immediate medical savings to offset its cost.

Employers are being asked to make a long-term investment while managing a short-term budget. The City of Dallas is a large public employer, but it faces the same basic problem as a private company: its plan has a limited budget, and when pharmacy and medical claims exceed expectations, it must find more money, cut elsewhere, change future benefits, or ask employees to contribute more.

Dallas is not alone

GLP-1 spending has become a national employer benefits issue. A 2026 Business Group on Health survey found nearly eight in 10 employers said GLP-1 medications were increasing their healthcare costs, and 67% covered the drugs for weight management. Employers also expected demand to keep growing: 87% believed the availability of oral GLP-1 medications would increase overall demand, and only 9% expected prices to decline.

The broader cost environment is already difficult. Employers projected a median healthcare cost increase of 9% for 2026 before plan changes, and 7.6% even after adjusting benefits. Pharmacy spending is rising even faster:

GLP-1s are not the only reason costs are rising — cancer treatment, specialty medications, mental health services, chronic conditions, and high-cost medical claims all add pressure. But GLP-1s are one of the most visible examples, because demand is growing rapidly and the cost is recurring.

Employers are beginning to reconsider coverage

Most employers don't want to deny effective treatment — but they also can't offer every treatment without weighing the financial consequences. Among employers covering GLP-1s for weight management, only 72% told the Business Group on Health they were likely to continue that coverage in 2027, and 10% said they were unlikely to.

Many aren't eliminating coverage; they're adding requirements meant to ensure the drugs reach patients most likely to benefit — prior authorization, confirmation of clinical eligibility, participation in a weight-management program, prescribing restrictions, and additional monitoring. Ninety percent of employers covering GLP-1s for obesity reported using prior authorization, more than half required a weight-management program, and nearly half required certain BMI levels or additional health conditions.

These controls can manage utilization, but they can also frustrate patients and doctors. An employee may get a physician's recommendation and still face several administrative steps before approval. This is where the affordability debate becomes personal: for the employer it's a budget decision; for the patient it's a healthcare decision.

A successful medication can create a financial problem

The pressure around GLP-1 coverage reflects an unusual reality in American healthcare. The drugs are expensive partly because they're in high demand, and demand is high partly because many patients and physicians believe they work. A medication doesn't have to fail clinically to create a financial problem — it can be medically successful and financially difficult at the same time.

If only a few people use an expensive medication, a large employer may absorb the cost. If thousands of employees and dependents become eligible, the expense can materially affect the whole plan. The employer may then have to choose among hard options:

• Increase employee premiums.
• Raise deductibles or copayments.
• Restrict access to the medication.
• Reduce other benefits.
• Absorb the cost and accept lower profits or tighter public budgets.

None of these is painless — and even workers who never use a GLP-1 can be affected if the plan's overall spending rises.

High-cost claims make it even more complicated

It would be misleading to blame Dallas's entire overage on weight-loss drugs. The city also had several unusually expensive medical claims — a fundamental challenge of self-funded employer plans. Under a self-funded arrangement, the employer takes on responsibility for employees' medical and prescription claims rather than paying an insurer to assume all the risk. Stop-loss insurance can limit exposure to the largest claims, but the plan can still be volatile.

One premature birth, complex cancer treatment, transplant, specialty therapy, or extended hospitalization can cost hundreds of thousands or even millions of dollars. When several large claims land in the same year, the budget can change fast. That appears to be part of what happened in Dallas: GLP-1 utilization raised ongoing pharmacy expense while large medical claims added pressure, together turning an expected savings year into a significant deficit.

The cost may eventually reach employees and taxpayers

Dallas is a public employer, so its financial decisions affect more than its workforce. When a plan exceeds budget, the money ultimately comes from another city source, existing reserves, future budget adjustments, or higher employee contributions. That raises real public-policy questions: Should the city reduce access to medications that may improve employee health? Should employees pay a greater share? Should taxpayers absorb the cost? Should the plan be redesigned with stricter clinical requirements?

There's no simple answer. Restricting treatment could worsen health outcomes for some employees; covering it without effective cost controls could make the whole program harder to sustain. The objective shouldn't be to choose between employee health and financial responsibility — it should be to find a coverage model that supports both.

Employers need more than a yes-or-no decision

The GLP-1 debate is often framed as binary: cover the drug or don't. A more effective strategy usually needs several layers of plan management:

1. Set clear clinical eligibility standards, require appropriate medical oversight, and evaluate whether patients are receiving ongoing benefit.
2. Review pharmacy benefit manager contracts, rebate arrangements, and formulary pricing.
3. Analyze adherence — whether employees stay on the medication long enough to see meaningful results.
4. Coordinate coverage with nutrition, behavioral health, and chronic-condition programs instead of treating the prescription as an isolated benefit.
5. Examine purchasing arrangements for greater pricing transparency — the Business Group on Health has encouraged employers to evaluate alternative pharmacy benefit models, reduce reliance on opaque rebate structures, and require vendors to demonstrate measurable value.

The goal isn't to create unnecessary barriers. It's to ensure a high-cost treatment reaches appropriate patients and produces outcomes that justify the investment.

Employees also need clear communication

Coverage decisions around GLP-1s can create confusion. An employee may hear a plan covers Wegovy or Zepbound without understanding the prior authorization requirements. Another may assume Ozempic is automatically covered for weight loss when the plan covers it only for diabetes. Someone who begins treatment may not realize continued coverage requires a specific program or proof of ongoing clinical progress.

Employers should explain these distinctions clearly — which medications are covered, which diagnoses qualify, what approvals are required, and what costs to expect. Unexpected denials create frustration and can damage trust in the whole benefits program. Transparent communication won't eliminate the affordability problem, but it can keep employees from making healthcare decisions based on incorrect assumptions.

The larger American healthcare problem

Dallas's $17 million overage isn't simply a story about one city's budget. It illustrates the broader difficulty of financing medical innovation through employer-sponsored insurance. New treatments are being developed faster than employers can figure out how to pay for them. Some may prevent expensive diseases years in the future — but employers must pay for them through this year's plan. Some patients may see life-changing results — but covering every eligible patient could require major benefit changes for the entire workforce.

This tension won't be limited to weight-loss drugs. Employers are also confronting expensive cancer therapies, gene and cell treatments, specialty medications, and new tools for managing chronic disease. The healthcare system is becoming more capable. It is not necessarily becoming more affordable.

The real lesson from Dallas

The Dallas deficit shouldn't be read as proof that GLP-1 medications don't work or shouldn't be covered. It's evidence that the current financing system is struggling to absorb their rapid adoption. The drugs may provide meaningful clinical value; employees may legitimately need them; employers still have to figure out how to provide access without destabilizing the plan that covers everyone else.